{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010634","form_type":"8-K","ticker":"PMHS","cik":"0001265521","company_name":"Polomar Health Services, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.156917+00:00","generated_at":"2026-05-24T15:15:33.451449+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Polomar Health signs exclusive distribution deal for inhalable sildenafil and sumatriptan","bullets":["Agreement with ForHumanity Health and Island 40 Group grants exclusivity through Sep 30, 2025, in exchange for $750,000 guaranteed revenue.","ForHumanity made a $250,000 advance payment to secure exclusivity; remaining $500,000 due by June 30, 2025.","Initial term of 3 years through March 2028; auto-renewal for up to 5-year terms if revenue targets met (minimum $3M average annually for first renewal).","Exclusivity can be extended through Dec 31, 2028, if ForHumanity achieves escalating revenue milestones (e.g., $20M by 2027).","Polomar Specialty Pharmacy will fulfill prescriptions; IG4 handles account management."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010634","json":"https://secwatch.observer/filing/0001493152-25-010634.json","markdown":"https://secwatch.observer/filing/0001493152-25-010634.md","text":"https://secwatch.observer/filing/0001493152-25-010634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1265521/000149315225010634/0001493152-25-010634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1265521/000149315225010634/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:15:33.451449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}